NEW YORK (GenomeWeb News) – Berg Pharma will use its Integrative Biology platform to identify drug targets and biomarkers in clinical samples from the Parkinson's Institute of Sunnyvale, Calif., under a partnership announced today.

The Berg platform is used to compare and study normal and disease signatures by integrating a range of data sets, including genomic, metabolomic, proteomic, and lipidomic data. Under the partnership, Berg Pharma will have access to clinically annotated tissue samples representing various types of Parkinson's disease and specific mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: epigenetic changes linked with high-altitude pulmonary edema, transcriptome profiling of maize leaf development, and more.

Stanford University researchers are studying top athletes to uncover genes linked to performance.

The UW's Wylie Burke and Dartmouth's Gilbert Welch argue that whole-genome testing may do more harm than good, and a related poll.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.